title: Plerixafor injection: a hematopoietic stem cell mobilizer in non-Hodgkin lymphoma and multiple myeloma.
abstract: BACKGROUND
  A combination of granulocyte colony-stimulating factor (G-CSF) and chemotherapy or G-CSF alone are the most common mobilization regimens for autotransplantations. Plerixafor is used for mobilization of CD34(+) cells with G-CSF in non-Hodgkin lymphoma (NHL) and myeloma (MM) patients.
  
  
  METHODS
  The available phase II and III data on plerixafor has been reviewed. The efficacy of plerixafor in the mobilization of CD34(+) cells in predicted poor mobilizers as well as in patients who had failed a mobilization has been evaluated. The pre-emptive use of plerixafor as well as studies on cost-effectiveness are covered. Also effects in the composition of the collected grafts along with the data on long-term outcome of plerixafor-mobilized patients is discussed. Expert commentary: Plerixafor combined with G-CSF mobilizes CD34(+) cells more efficiently than G-CSF alone in patients with NHL or MM. In phase III studies, engraftment after high-dose therapy has been comparable to G-CSF mobilized patients. The pre-emptive use of plerixafor added to mobilization with chemotherapy plus G-CSF or with G-CSF alone has gained more popularity. This approach may be more cost-effective than the routine use of this drug. The changes observed in the composition of grafts after plerixafor injection may have implications for post-transplant events.
authors.affiliation: a Department of Medicine , Kuopio University Hospital , Kuopio , Finland.
authors.forename: Esa
authors.initials: E
authors.lastname: Jantunen
authors.affiliation: b Department of Medicine , Kymenlaakso Central Hospital , Kotka , Finland.
authors.forename: Ville
authors.initials: V
authors.lastname: Varmavuo
authors.affiliation: a Department of Medicine , Kuopio University Hospital , Kuopio , Finland.
authors.forename: Jaakko
authors.initials: J
authors.lastname: Valtola
mesh_terms: D018952:Antigens, CD34; D001596:Benzylamines; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D003362:Cost-Benefit Analysis; D000080027:Cyclams; D019650:Hematopoietic Stem Cell Mobilization / Q000379:methods; D018380:Hematopoietic Stem Cell Transplantation; D006412:Hematopoietic Stem Cells / Q000187:drug effects* / Q000378:metabolism; D006571:Heterocyclic Compounds / Q000008:administration & dosage* / Q000494:pharmacology; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000628:therapy*; D009101:Multiple Myeloma / Q000628:therapy*; D011292:Premedication; D016896:Treatment Outcome
chemical_list: D018952:Antigens, CD34; D001596:Benzylamines; D000080027:Cyclams; D006571:Heterocyclic Compounds; C088327:plerixafor
keywords: Plerixafor; costs; graft content; lymphoma; myeloma; outcome; poor mobilization; stem cell mobilization